Drugs / SKY-GJB2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07627971 | May 2026 → Dec 2027 expected | autosomal recessive nonsyndromic hearing loss 1A | Skylark Bio Inc. | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-08-11 | Skylark Bio Inc. | Skylark Bio Doses First Patient in SONIX Phase 1/2 Trial of SKY-GJB2 for GJB2-Related Pediatric Deafness skylarkbio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SKY-GJB2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07627971 ↗ |
| Route | Other | “one-time unilateral intracochlear infusion” NCT07627971 ↗ |